---
title: "Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings"
description: "Weiss Ratings reaffirmed a \"sell (d-)\" rating on shares of Merus in a research note on Wednesday."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260641126.md"
published_at: "2025-10-10T12:56:47.000Z"
---

# Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings

> Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Merus in a research note on Wednesday.

Merus (NASDAQ:MRUS - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also issued reports about the stock. Guggenheim reissued a "neutral" rating and issued a $97.00 target price (down from $109.00) on shares of Merus in a report on Tuesday, September 30th. Truist Financial lowered shares of Merus from a "buy" rating to a "hold" rating and increased their target price for the stock from $88.00 to $97.00 in a report on Monday, September 29th. UBS Group lowered shares of Merus from a "buy" rating to a "neutral" rating and increased their target price for the stock from $72.00 to $97.00 in a report on Tuesday, September 30th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a report on Monday, August 25th. Finally, Canaccord Genuity Group lowered shares of Merus from a "buy" rating to a "hold" rating and increased their target price for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Merus currently has an average rating of "Hold" and an average price target of $93.12.

**Get Our Latest Research Report on Merus**

## Merus Stock Down 0.0%

NASDAQ MRUS opened at $94.38 on Wednesday. Merus has a 52 week low of $33.19 and a 52 week high of $94.56. The firm has a market capitalization of $7.14 billion, a P/E ratio of -17.16 and a beta of 1.26. The company has a 50-day moving average price of $71.20 and a 200-day moving average price of $57.01.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The business had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. As a group, equities research analysts anticipate that Merus will post -3.85 EPS for the current year.

## Insiders Place Their Bets

In other Merus news, COO Peter B. Silverman sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.70% of the stock is owned by insiders.

## Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 603 shares during the last quarter. CWM LLC boosted its position in shares of Merus by 299.0% during the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. GF Fund Management CO. LTD. boosted its position in shares of Merus by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 315 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company's stock valued at $141,000 after acquiring an additional 362 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

## Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

## Further Reading

-   Five stocks we like better than Merus
-   What is a Death Cross in Stocks?
-   5 Healthcare Plays Powering the Sector’s Big Comeback
-   What is a buyback in stocks? A comprehensive guide for investors
-   Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?
-   2 Rising CRM Platform Stocks That Can Surge Higher in 2025
-   Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Merus Right Now?

Before you consider Merus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.

While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [MRUS.US - Merus BV](https://longbridge.com/en/quote/MRUS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merus Power 赢得了 Neve Oy 价值 1300 万欧元的储能合同 | Merus Power Oyj 与 Neve Oy 签署了一份价值 1300 万欧元的合同，旨在建设一个电池储能系统。该项目涉及在芬兰罗瓦涅米建设一个 30 MW/80 MWh 的设施，设计用于极端北极条件，预计将在 2026 年底前交付。 | [Link](https://longbridge.com/en/news/275563767.md) |
| SpaceX 向国际空间站发射第 12 批长期驻留的乘组 | SpaceX 于 2023 年 2 月 13 日成功发射了第 12 次长期载人任务前往国际空间站（ISS）。此次任务的乘组由两名美国宇航员、一名法国宇航员和一名俄罗斯宇航员组成，计划进行为期八个月的科学任务。猎鹰 9 号火箭从佛罗里达州的卡 | [Link](https://longbridge.com/en/news/275892766.md) |
| 高盛首席执行官谈美国经济时表示，我们有能力以更高的基础增长率运行 | 高盛首席执行官谈美国经济表示，我们有能力以更高的基础增长率运行 | [Link](https://longbridge.com/en/news/275913168.md) |
| NBC 报道，委内瑞拉领导人罗德里格斯表示她受邀访问美国 | 华盛顿，2 月 12 日（路透社）- 委内瑞拉临时领导人总统德尔西·罗德里格斯表示，她已被邀请前往美国，NBC 新闻在周四发布的一次采访中报道了这一消息，此时美国能源部长克里斯·赖特正在卡拉卡斯访问。“我已被邀请前往美国，” 罗德里格斯被引 | [Link](https://longbridge.com/en/news/275755066.md) |
| Meta 显然认为我们过于分心，以至于不在乎面部识别技术和 Ray-Bans 眼镜 | Meta 显然认为我们太分心了，不会关心面部识别和 Ray-Bans | [Link](https://longbridge.com/en/news/275950478.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
